Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.

BACKGROUND: To date, there has been no systematic examination of the relationship between international normalized ratio (INR) control measurements and the prediction of adverse events in patients with atrial fibrillation on oral anticoagulation. METHODS AND RESULTS: We searched MEDLINE, EMBASE, an...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Wan, Y, Heneghan, C, Perera, R, Roberts, N, Hollowell, J, Glasziou, P, Bankhead, C, Xu, Y
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2008

Gelijkaardige items

Adverse events in clinically complex elderly patients with atrial fibrillation according to oral anticoagulation statusResearch in context
door: Tommaso Bucci, et al.
Gepubliceerd in: (2024-12-01)

Rhythm control agents and adverse events in patients with atrial fibrillation.
door: Taylor, C, et al.
Gepubliceerd in: (2010)

Individualised prediction of major bleeding in patients with atrial fibrillation treated with anticoagulation
door: Anne Pernille Toft-Petersen, et al.
Gepubliceerd in: (2024-01-01)

Individualised prediction of major bleeding in patients with atrial fibrillation treated with anticoagulation.
door: Anne Pernille Toft-Petersen, et al.
Gepubliceerd in: (2024-01-01)

Anticoagulant management in patients with atrial fibrillation.
door: Fitzmaurice, D, et al.
Gepubliceerd in: (2009)

Machine Learning Approaches to Predict Major Adverse Cardiovascular Events in Atrial Fibrillation
door: Pedro Moltó-Balado, et al.
Gepubliceerd in: (2024-01-01)

3021 Haemodialysis and atrial fibrillation anticoagulation decisions
door: Stephen Bacchi, et al.
Gepubliceerd in: (2024-08-01)

Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation
door: Ding J, et al.
Gepubliceerd in: (2024-02-01)

Coffee consumption and adverse cardiovascular events in patients with atrial fibrillation
door: Vasco Iten, et al.
Gepubliceerd in: (2024-12-01)

Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation
door: Yiin, G, et al.
Gepubliceerd in: (2018)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
door: I. Yu. Koroleva, et al.
Gepubliceerd in: (2016-11-01)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
door: Yu. P. Skirdenko, et al.
Gepubliceerd in: (2020-05-01)

Atrial Fibrillation Ablation without Interruption of Anticoagulation
door: Pasquale Santangeli, et al.
Gepubliceerd in: (2011-01-01)

Challenging anticoagulation decisions in atrial fibrillation: a narrative review
door: Michael Griffin, et al.
Gepubliceerd in: (2024-10-01)

Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation
door: Xue Zhou, et al.
Gepubliceerd in: (2020-01-01)

A systematic review of economic aspects of service interventions to increase anticoagulation use in atrial fibrillation
door: Jones, NR, et al.
Gepubliceerd in: (2021)

Underuse of anticoagulation for atrial fibrillation - are we failing our patients?
door: Jones, N, et al.
Gepubliceerd in: (2017)

Atrial fibrillation – NICE 2021 update and the focus on anticoagulation
door: Jones, N, et al.
Gepubliceerd in: (2022)

CURRENT POSSIBILITIES OF ANTICOAGULANT THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION
door: M. Yu. Gilyarov, et al.
Gepubliceerd in: (2015-10-01)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage
door: A. S. Gerasimenko, et al.
Gepubliceerd in: (2021-05-01)

Challenges of anticoagulant treatment in atrial fibrillation with liver disease
door: Alina Doina Nicoara, et al.
Gepubliceerd in: (2024-10-01)

Anticoagulant therapy in catheter ablation of atrial fibrillation and flutter
door: M. V. Serova, et al.
Gepubliceerd in: (2021-09-01)

Anticoagulation for Atrial Fibrillation in Acute Coronary Syndrome Survivors Reduces Major Cardiovascular Events and Mortality
door: Łukasz Pyka MD, PhD, et al.
Gepubliceerd in: (2023-12-01)

Self-monitoring of oral anticoagulation: a systematic review and meta-analysis.
door: Heneghan, C, et al.
Gepubliceerd in: (2006)

Sex-specific comparative outcomes between oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
door: Gregory Y H Lip, et al.
Gepubliceerd in: (2024-08-01)

Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?
door: Tahmeed Contractor, et al.
Gepubliceerd in: (2011-01-01)

Moderate/severe biatrial dilation predicts adverse events after ablation in atrial fibrillation with heart failure
door: Yan Yao, et al.
Gepubliceerd in: (2024-10-01)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
door: Raffaele De Caterina, et al.
Gepubliceerd in: (2019-03-01)

PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS
door: A. А. Sokolova, et al.
Gepubliceerd in: (2017-12-01)

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
door: Jennifer R. Brown, et al.
Gepubliceerd in: (2017-10-01)

Challenges of anticoagulant therapy in patients with atrial fibrillation in clinical practice.
door: Hobbs, R
Gepubliceerd in: (2012)

ANTICOAGULATION IN PATIENTS WITH ATRIAL-FIBRILLATION - EXPERT SOFTWARE MAY BE THE ANSWER
door: Fitzmaurice, D, et al.
Gepubliceerd in: (1994)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
door: Z. D. Kobalava, et al.
Gepubliceerd in: (2021-03-01)

THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY
door: M. Yu. Gilyarov
Gepubliceerd in: (2015-12-01)

Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation
door: Dana Prídavková, et al.
Gepubliceerd in: (2019-01-01)

Factors determining adherence to anticoagulant therapy in patients with atrial fibrillation
door: D. V. Pevzner, et al.
Gepubliceerd in: (2023-06-01)

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease
door: N. Sh. Zagidullin, et al.
Gepubliceerd in: (2021-10-01)

NOVEL ANTICOAGULANTS FOR THROMBOEMBOLIC COMPLICATIONS PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
door: D. A. Itkin, et al.
Gepubliceerd in: (2015-02-01)

Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation
door: Yu. P. Skirdenko, et al.
Gepubliceerd in: (2019-03-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
door: E. I. Baranova
Gepubliceerd in: (2018-11-01)